statistiche ricercatore

Nome	#
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors	85
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents	71
Mechanisms of resistance to mTOR inhibitors	42
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.	41
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer	37
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex	36
Approaches for targeting cancer stem cells drug resistance	36
Mechanisms of lapatinib resistance in HER2-driven breast cancer	35
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action	34
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.	30
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer.	26
Integr(at)in(g) EGFR therapy in HNSCC	24
In Vitro and in Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies.	20
EGFR-targeting agents in oncology	19
High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs.	16
Totale	552

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	1	0	0	0	0	0	0	0	0	0	0	1	0
2019/2020	74	26	0	2	6	7	2	0	1	1	2	17	10
2020/2021	38	1	0	2	0	4	8	2	5	6	0	6	4
2021/2022	105	0	0	3	13	1	1	1	6	18	9	25	28
2022/2023	152	15	12	8	8	23	23	1	14	24	15	4	5
2023/2024	69	3	12	13	7	4	11	0	15	0	2	2	0
Totale													552